LivaNova PLC $LIVN Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in shares of LivaNova PLC (NASDAQ:LIVN) by 43.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,568 shares of the company’s stock after acquiring an additional 10,530 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.06% of LivaNova worth $1,811,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Bayforest Capital Ltd raised its stake in shares of LivaNova by 44.8% in the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after buying an additional 284 shares in the last quarter. State of Michigan Retirement System lifted its position in LivaNova by 2.3% in the 2nd quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock worth $590,000 after buying an additional 300 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of LivaNova by 182.5% during the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock valued at $28,000 after buying an additional 407 shares during the last quarter. California State Teachers Retirement System boosted its holdings in LivaNova by 0.9% in the second quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after purchasing an additional 458 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its position in LivaNova by 0.8% during the second quarter. Retirement Systems of Alabama now owns 66,644 shares of the company’s stock worth $3,000,000 after purchasing an additional 554 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LIVN has been the subject of several research analyst reports. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Mizuho lifted their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Stifel Nicolaus raised their target price on LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. Finally, Robert W. Baird set a $75.00 price objective on LivaNova in a report on Tuesday, December 16th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $69.38.

LivaNova Stock Up 1.3%

LivaNova stock opened at $64.71 on Friday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $65.57. The firm has a market capitalization of $3.53 billion, a PE ratio of -16.18 and a beta of 0.97. The company’s 50-day moving average is $62.88 and its 200-day moving average is $55.69. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.